[Biologic-psychiatric considerations for treatment of disturbances of sexual impotence (author's transl)].
D000328:Adult; D000818:Animals; D001921:Brain / Q000187:drug effects; D002262:Carboxy-Lyases / Q000037:antagonists & inhibitors; D002986:Clinical Trials as Topic; D013196:Dihydrotestosterone / Q000494:pharmacology / Q000627:therapeutic use*; D004295:Dihydroxyphenylalanine / Q000494:pharmacology / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism; D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000188:drug therapy*; D010134:Fenclonine / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009638:Norepinephrine / Q000378:metabolism; D010919:Placebos; D051381:Rats; D012701:Serotonin / Q000378:metabolism; D012702:Serotonin Antagonists; D012725:Sexual Behavior / Q000187:drug effects*; D012726:Sexual Behavior, Animal / Q000187:drug effects*; D013268:Stimulation, Chemical; D013739:Testosterone / Q000494:pharmacology / Q000627:therapeutic use
D010919:Placebos; D012702:Serotonin Antagonists; D013196:Dihydrotestosterone; D012701:Serotonin; D013739:Testosterone; D004295:Dihydroxyphenylalanine; D002262:Carboxy-Lyases; D010134:Fenclonine; D004298:Dopamine; D009638:Norepinephrine
Biologisch-psychiatrischer Ansatz zur Therapie von Potenzstörungen.